Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Lipson (Collegeville and Philadelphia, United States of America), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, MI, United States of America), C. Jones (Research Triangle Park, NC, United States of America), S. Kilbride (Stockley Park, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lomas (London, United Kingdom), F. Martinez (New York, NY, United States of America), H. Quasny (Research Triangle Park, NC, United States of America), D. Singh (Manchester, United Kingdom), R. Wise (Baltimore, MD, United States of America). The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time. 2482

Member's Comments

No comment yet.

Related content which might interest you: The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Effect of High-Flow Oxygen on Exercise Performance In COPD. A Randomized Crossover Trial. Source: Virtual Congress 2020 – New insights into evaluation and treatment of respiratory disease Year: 2020 Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Late Breaking Abstract - Effects of long-term Tobramycin Inhalation Solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. The BATTLE Randomized Controlled Trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020 Late Breaking Abstract - TriOptimize VIII – Improvement of Lung Function with Extrafine Single Inhaler Triple Therapy – Analysis of Response Patterns by Prior Treatment from a Real-World Study. Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 BREEZE: Open-label, Clinical Study to Evaluate the Safety and Tolerability of a Treprostinil Dry Powder Inhaler in Patients with Pulmonary Arterial Hypertension Currently Using Tyvaso Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Late Breaking Abstract - Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Late Breaking Abstract - Real-world evidence of dual bronchodilator therapy using Clinical COPD Questionnaire in 4700 COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Safety and Feasibility of Metered CryoSpray (MCS) for Patients with Chronic Bronchitis in COPD: 9 Month Results. Source: International Congress 2019 – Bronchoscopic treatment of COPD: hot news Year: 2019 FENO Guided Therapy in Asthma: A Non-inferiority Study Source: International Congress 2019 – Eosinophils and FeNO in airway diseases Year: 2019 Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Evolution in the prescription of the therapy combined with ICS-LABA in COPD: TRACE STUDY Source: International Congress 2017 – Markers of COPD progression Year: 2017 Curcumin Improves Therapy of Moderate Partially Controlled Asthma: Placebo-controlled, single blind study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Patient preference for COPD treatment inhalers: A Discrete Choice Experiment (DCE) in France – Results of a Pilot Study Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kd) GSK2269557, Delivered via the ELLIPTATM Device to Healthy Subjects in a Phase I Trial, Including Charcoal Block. Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017